4D Mol­e­c­u­lar Ther­a­peu­tic­s' gene ther­a­py cuts Eylea use in wet AMD pa­tients, biotech di­vulges plans for piv­otal stud­ies

4D Mol­e­c­u­lar Ther­a­peu­tics said peo­ple with wet age-re­lat­ed mac­u­lar de­gen­er­a­tion (AMD) who re­ceived the com­pa­ny’s gene ther­a­py as part of a clin­i­cal tri­al need­ed few­er in­jec­tions of Eylea, a sta­ple treat­ment for the eye dis­ease.

In the Phase II PRISM study, 51 pa­tients with wet AMD re­ceived ei­ther 4D’s gene ther­a­py or their usu­al in­jec­tions of Eylea, a block­buster med­i­cine mar­ket­ed by Re­gen­eron. Over 24 weeks, 63% of the pa­tients who re­ceived a high dose of the gene ther­a­py, dubbed 4D-150, and 50% of those who re­ceived the low dose did not need sup­ple­men­tal Eylea in­jec­tions.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER